Biometric Imaging Selects Immucor As Exclusive Distributor For New Cell-Based Assay Technology.MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Jan. 9, 1997--Biometric Imaging Inc., developer and manufacturer of a novel cellular analysis system, today announced the signing of an exclusive distribution agreement with Immucor Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BLUD BLUD Be Loyal Until Death (gaming clan) ) to market Biometric Imaging's products in the U.S., Canada and Europe. Immucor manufactures and sells blood bank reagent reagent /re·a·gent/ (re-a´jent) a substance used to produce a chemical reaction so as to detect, measure, produce, etc., other substances. re·a·gent n. systems and related products to hospitals and donor centers under its own brand, and will market the new cellular analysis system under the Biometric Imaging name. Biometric Imaging will handle manufacturing and regulatory functions and provide Immucor with ongoing sales and technical support. The three-year renewable agreement commences immediately and calls for yearly minimum purchases by Immucor. The relationship is being launched with a sales training program for Immucor's 50 plus-person direct sales force by Biometric Imaging. "This distribution agreement gives Biometric Imaging immediate access to our key markets in cell therapy and HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. monitoring through sales people who are well-known by our potential customers," said Christopher B. M. English, president of Biometric Imaging. "Immucor has the established relationships needed to get attention for our new technology." Biometric Imaging's automated cellular analysis system includes the IMAGN 2000 microvolume fluorimeter fluorimeter /flu·o·rim·e·ter/ (fldbobr-rim´e-ter) fluorometer. fluorimeter see fluorometer. and three cell-specific enumeration 1. (mathematics) enumeration - A bijection with the natural numbers; a counted set. Compare well-ordered. 2. (programming) enumeration - enumerated type. assays. The STELLer assay standardizes, for the first time, a method for counting CD34+ cells, helping to reduce the costs and improve the outcomes of stem cell transplantations Stem Cell Transplantation Definition Stem cells are basic human cells that reproduce (replicate) easily, providing a continuous source of new, sometimes different types of cells. . The CEQer product line automates the enumeration of residual white blood cells White blood cells A group of several cell types that occur in the bloodstream and are essential for a properly functioning immune system. Mentioned in: Abscess Incision & Drainage, Bone Marrow Transplantation, Complement Deficiencies in blood products, allowing blood centers to efficiently meet the growing demand for leukocyte-reduced blood components. The 4T8 assay provides precise CD4+ T-lymphocyte counts in a one-step whole-blood assay, allowing physicians to guide therapy and validate new treatment strategies. The IMAGN 2000 microvolume fluorimeter and all three assays will be marketed by Immucor in Europe and Canada. In the U.S., Immucor will launch the 4T8 and CEQer assays immediately and will add new products as they become available. Founded in 1991, Biometric Imaging is the first company to address the critical need for standardized standardized pertaining to data that have been submitted to standardization procedures. standardized morbidity rate see morbidity rate. standardized mortality rate see mortality rate. cellular analysis procedures in the emerging field of cell therapy. Cell therapy uses transfused cells from a patient or donor to achieve a desired therapeutic effect in diseases such as cancer and AIDS. The company has developed and is marketing a novel, enabling technology called microvolume fluorimetry to provide rapid, precise and easy-to-perform cell enumeration, as well as real-time cell characterization in routine clinical settings. Biometric Imaging's products are designed to: 1) help ensure the integrity of transfused products; 2) optimize cell therapy procedures; and 3) monitor disease progression and the efficacy of therapy. CONTACT: Marketing Plus Siga Weber, 415/421-8200 or Biometric Imaging Christina Lowell, 415/903-5870 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion